This drug has a very high likelihood of success.
It brings attention back to a lot of the risks in pharmaceuticals right now with regards to drug safety.
It's wide open, ... The obesity market is unique in that it is probably the largest market in the world. However, nothing really works well in terms of safety and tolerability.
[The market] is under-performing in terms of sales because it's tough to find something that works.
It's a drop in the bucket. It's helping the stock price today, but gastric cancer is not one of the biggest markets for cancer.
The ones that are lost will probably be lost for good.
These are high-risk, high-reward [vaccines]. The chances of their success are remote, but if they do work, we would expect them to be blockbusters if they produced enough to supply developed nations and undeveloped nations.
It left us with a flawed system where they try to get there first and they challenge patents even if they feel they're not going to win. The system is broken.
From an R&D perspective, they've actually got the first or second largest cancer pipeline in the world. So, they're moving in the right direction.
Copyright © 2024 Electric Goat Media. All Rights Reserved.